In Response to: "Comparing Addition of Radiotherapy in EGFR- and ALK-Positive NSCLC With Brain Metastases: Are We Evaluating the Optimal Endpoint?"

Affiliations

• ¹ Division of Medical Oncology, UCSF Helen Diller Comprehensive Cancer Center, San Francisco, California.
• ² Division of Oncology, Department of Medicine, Stanford University, Stanford, California.
• ³ Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado.
• ⁴ Department of Radiation Oncology, University of California San Francisco, San Francisco, California.
• ⁵ Department of Radiation Oncology, Stanford Cancer Institute, Stanford, California.
• ⁶ Department of Neurology, Stanford University, Stanford, California.
• ⁷ Department of Radiation Oncology, University of Colorado School of Medicine, Aurora, Colorado.
• ⁸ Division of Hematology/Oncology, University of California San Francisco, San Francisco, California; Genentech Inc., South San Francisco, California. Electronic address: caroline.mccoach@ucsf.edu.